Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study
Abstract
Authors
A. Valladares J.L. Calleja M.Á Serra F. Chacón G. Nocea